Herantis Pharma Plc – Press release 23 February, 2026 at 14:45 EET

Herantis Pharma to publish financial statements 2025 on 5 March 2026 – invitation to webcast presentation

Espoo, Finland, 23 February 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that it will publish its financial statements for 2025 on Thursday, 5 March 2026.

Herantis CEO Antti Vuolanto and CFO Tone Kvåle will host a webcast relating to the report and current operations on Thursday, 5 March 2026, at 10:00 am EET (9:00 am CET). The presentation will be in English and will conclude with a Q&A session. Questions can be submitted throughout the webcast event.

Attendees are invited to register and join the online event using the following link: https://herantis.videosync.fi/q4-2025/register

A recording of the webcast will be available on the Company’s website after the event has concluded: https://herantis.com/news-events/video-presentations/

For more information, please contact:

Herantis Pharma Plc

Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

ICR Healthcare
Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage
Tel: +44 20 3709 5700
Email: herantispharma@icrhealthcare.com

Certified Advisor:

UB Corporate Finance Ltd

Tel: +358 9 25 380 225

Email: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.

Herantis is listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com